JP2020518582A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518582A5
JP2020518582A5 JP2019559304A JP2019559304A JP2020518582A5 JP 2020518582 A5 JP2020518582 A5 JP 2020518582A5 JP 2019559304 A JP2019559304 A JP 2019559304A JP 2019559304 A JP2019559304 A JP 2019559304A JP 2020518582 A5 JP2020518582 A5 JP 2020518582A5
Authority
JP
Japan
Prior art keywords
crystalline
hydrate
pharmaceutical composition
succinate
oxalate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019559304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518582A (ja
JP7096268B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/030144 external-priority patent/WO2018204236A1/en
Publication of JP2020518582A publication Critical patent/JP2020518582A/ja
Publication of JP2020518582A5 publication Critical patent/JP2020518582A5/ja
Application granted granted Critical
Publication of JP7096268B2 publication Critical patent/JP7096268B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019559304A 2017-05-01 2018-04-30 Jak阻害剤化合物の結晶形態 Expired - Fee Related JP7096268B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762492571P 2017-05-01 2017-05-01
US62/492,571 2017-05-01
PCT/US2018/030144 WO2018204236A1 (en) 2017-05-01 2018-04-30 Crystalline forms of a jak inhibitor compound

Publications (3)

Publication Number Publication Date
JP2020518582A JP2020518582A (ja) 2020-06-25
JP2020518582A5 true JP2020518582A5 (cg-RX-API-DMAC7.html) 2021-05-06
JP7096268B2 JP7096268B2 (ja) 2022-07-05

Family

ID=62165729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019559304A Expired - Fee Related JP7096268B2 (ja) 2017-05-01 2018-04-30 Jak阻害剤化合物の結晶形態

Country Status (13)

Country Link
US (1) US10251874B2 (cg-RX-API-DMAC7.html)
EP (1) EP3619208B1 (cg-RX-API-DMAC7.html)
JP (1) JP7096268B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200003121A (cg-RX-API-DMAC7.html)
CN (1) CN110603255B (cg-RX-API-DMAC7.html)
AU (1) AU2018261591B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059790A1 (cg-RX-API-DMAC7.html)
MX (1) MX389014B (cg-RX-API-DMAC7.html)
MY (1) MY200348A (cg-RX-API-DMAC7.html)
PH (1) PH12019502425A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201909376TA (cg-RX-API-DMAC7.html)
TW (1) TWI808083B (cg-RX-API-DMAC7.html)
WO (1) WO2018204236A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
TWI754019B (zh) 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
BR112021004063A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários
DK3837258T3 (da) 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
EP3853229A1 (en) 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
KR20220149585A (ko) 2020-03-02 2022-11-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제 화합물의 결정성 수화물
CA3212635A1 (en) * 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CN118401508A (zh) * 2021-12-17 2024-07-26 株式会社大熊制药 (2R,3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
CA2756989A1 (en) 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
DK3712152T3 (da) 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
EP3831830A1 (en) 2015-11-03 2021-06-09 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
TWI710560B (zh) * 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物

Similar Documents

Publication Publication Date Title
JP2023516640A5 (cg-RX-API-DMAC7.html)
JP2020518581A5 (cg-RX-API-DMAC7.html)
JP2021535177A5 (cg-RX-API-DMAC7.html)
JP5416408B2 (ja) 5−クロロ−n−({(5s)−2−オキソ−3−[4−(3−オキソ−4−モルホリニル)−フェニル]−1,3−オキサゾリジン−5−イル}−メチル)−2−チオフェンカルボキサミドの新規多形および無定形
CN112638877B (zh) 用于治疗rna病毒感染的苯基/吡啶基-n-苯基/吡啶基衍生物
JP2021535174A5 (cg-RX-API-DMAC7.html)
JP2016500111A5 (cg-RX-API-DMAC7.html)
JP2018531982A5 (cg-RX-API-DMAC7.html)
JP2021504338A5 (cg-RX-API-DMAC7.html)
JP2015145426A5 (cg-RX-API-DMAC7.html)
JP2012532112A5 (cg-RX-API-DMAC7.html)
JP2022502500A5 (cg-RX-API-DMAC7.html)
JP2013542937A5 (cg-RX-API-DMAC7.html)
JP2016529306A5 (cg-RX-API-DMAC7.html)
JP2013538857A5 (cg-RX-API-DMAC7.html)
JP2019509268A5 (cg-RX-API-DMAC7.html)
JP2019505529A5 (cg-RX-API-DMAC7.html)
JP2020521732A5 (cg-RX-API-DMAC7.html)
FI3837258T3 (fi) Dimetyyliaminoatsetidiiniamideja jak-estäjinä
TW200304824A (en) Nicotinamide derivatives useful as PDE4 inhibitors
RU2014135759A (ru) Конденсированные пирролдикарбоксамиды и их применение в качестве фармацевтических средств
JP2013541592A5 (cg-RX-API-DMAC7.html)
JP2013508385A5 (cg-RX-API-DMAC7.html)
JP2016516691A5 (cg-RX-API-DMAC7.html)
JP2018522945A5 (cg-RX-API-DMAC7.html)